Private Equity-Backed Crealta Makes Its First Move With Savient Deal
This article was originally published in The Pink Sheet Daily
Executive Summary
A startup called Crealta Pharmaceuticals will acquire most of Savient’s assets, including the marketed gout drug Krystexxa, for $120.4 million following a bankruptcy court auction.
You may also be interested in...
Start-Up Quarterly Statistics, Q4 2013
Life science start-ups raised $1.18 billion in the final quarter of 2013, more than twice the $559.4 million they garnered in the previous quarter, and the most lucrative quarter reported for the group in the history of this START-UP column.
Regeneron Likely Facing New Gout Study Following Arcalyst “Complete Response” Letter
FDA’s decision not to approve rilonacept for preventing gout flares was unsurprising, given its Arthritis Advisory Committee’s unanimous recommendation against the indication. Regeneron says FDA’s letter requests “additional clinical data,” as well as chemistry, manufacturing and controls information.
Savient's New CEO Johnson Tasked With Turning Krystexxa Into A Commercial Success
Eli Lilly's oncology head John Johnson has been named to the top post at Savient Pharmaceuticals as the company tries to rebound from a failed sales attempt.